Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Longboard Pharmaceuticals Inc (NQ: LBPH )

59.50 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longboard Pharmaceuticals Inc

< Previous 1 2 3 4 5 Next >
LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH
From Kahn Swick & Foti, LLC
Via Business Wire
Deal Dispatch: Altus Power, Motorsport Games Explore Options, True Value Goes Bankrupt, M&A Activity Lags
S&P Global's Joe Mantone puts the latest M&A data in perspective and how deal pros might react post-Election Day. 
Via Benzinga
Topics Bankruptcy Stocks
Exposures Financial Legal US Equities
Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?
These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio? 
Via Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Bright Minds Biosciences Stock Surges Almost 1,500%
Bright Minds Biosciences (NASDAQ: DRUG) soared 1,445% in a single day, trading over 100 million shares without any news. 
Via MarketBeat
LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH
From Kahn Swick & Foti, LLC
Via Business Wire
Dow Surges Over 200 Points; Longboard Pharmaceuticals Shares Jump
Via Benzinga
Topics Stocks
Exposures US Equities
NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Government
Exposures Political
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Top 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Record
Lundbeck will buy Longboard Pharmaceuticals in a deal slated to close in the fourth quarter. 
Via Investor's Business Daily
Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading Higher On Monday?
H. Lundbeck acquires Longboard Pharmaceuticals for $2.6 billion. The acquisition strengthens Lundbeck's pipeline with bexicaserin, a potential treatment for Dravet syndrome and other neurological... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Shareholder Alert: Ademi LLP Investigates Whether Longboard Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
From Ademi LLP
Via Business Wire
LBPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Longboard Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Starbucks To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
Truist Securities initiated coverage on Longboard Pharmaceuticals, citing it as a CNS-focused biotech with high-value epilepsy assets. 
Via Benzinga
Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
From Longboard Pharmaceuticals, Inc.
Via Business Wire
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
These three small-cap stocks could deliver hefty returns if the central bank cuts rates. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.